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Introduction
Smoking is a leading cause of mortality and the leading 
cause of preventable death in Canada [1]. Smoking results 
in an increased risk of all- cause and cancer- specific mor-
tality [2]. At a global level, approximately nine million 
premature deaths per year may be attributed to smoking 
[3]. In Ontario, Canada, approximately 77,000 new cancer 
cases are diagnosed each year [4]. Approximately 20% of 
these persons are current smokers at the time of cancer 
diagnosis and 30–60% of them continue smoking after 
diagnosis [5]. Evidence suggests that the risk of dying 
from cancer could be lowered by 30–40% by quitting 
smoking at the time of cancer diagnosis [2]. Quitting 
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Abstract
Quitting smoking after a diagnosis of cancer results in greater response to treat-
ment and decreased risk of disease recurrence and second primary cancers. The 
objective of this study was to evaluate the potential cost- effectiveness of two 
smoking cessation approaches: the current basic smoking cessation program 
consisting of screening for tobacco use, advice, and referral; and a best practice 
smoking cessation program that includes the current basic program with the 
addition of pharmacological therapy, counseling, and follow- up. A Markov model 
was constructed that followed 65- year- old smokers with cancer over a lifetime 
horizon. Transition probabilities and mortality estimates were obtained from 
the published literature. Costs were obtained from standard costing sources in 
Ontario and reports. Probabilistic and deterministic sensitivity analyses were 
conducted to address parameter uncertainties. For smokers with cancer, the 
best practice smoking cessation program was more effective and more costly 
than the basic smoking cessation program. The incremental cost- effectiveness 
ratio of the best practice smoking cessation program compared to the basic 
smoking cessation program was $3367 per QALY gained and $5050 per LY 
gained for males, and $2050 per QALY gained and $4100 per LY gained for 
females. Results were most sensitive to the hazard ratio of mortality for former 
and current smokers, the probability of quitting smoking through participation 
in the program and smoking- attributable costs. The study results suggested that 
a best practice smoking cessation program could be a cost- effective option. 
These findings can support and guide implementation of smoking cessation 
programs.
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smoking at diagnosis improves prognosis and results in 
improved general health, reduced toxicity from treatment, 
greater response to treatment and decreased risk of disease 
recurrence and second primary cancers [6].
Illnesses that result from smoking are responsible for 
considerable health care costs, as well as loss of produc-
tivity from work. The societal cost of tobacco use in 
Canada in 2002 was estimated to be approximately 17 
billion Canadian dollars [7]. According to a report pub-
lished by the Institute for Clinical Evaluative Sciences and 
Public Health Ontario, smoking results in a loss of an 
average of 2.0–2.5 years of life expectancy for Ontarians 
[8]. As a result of the considerable social and economic 
burden of smoking, governments have undertaken smok-
ing cessation initiatives with the objective of lowering the 
smoking prevalence rates [7]. Initiatives have included 
media campaigns on the adverse effects of smoking, tax 
increases and packaging/marketing of tobacco products, 
telephone quit- lines for cessation support and school and 
community- based programs [9].
Pharmacological interventions and counseling are impor-
tant components of a smoking cessation program and 
evaluations of these programs have consistently demon-
strated the effectiveness and importance of physician based- 
interventions. Cancer Care Ontario, the provincial agency 
responsible for improving cancer services in Ontario, is 
currently implementing a best practice smoking cessation 
intervention for new ambulatory cancer patients presenting 
to its 14 Regional Cancer Programs. All 14 Regional Cancer 
Programs are currently screening patients for smoking 
status, advising on the benefits of quitting and offering 
referrals to smoking cessation resources. Smokers are advised 
that quitting tobacco use will benefit their general health, 
improve cancer treatment outcomes, and reduce the chance 
of developing comorbidities. Data on screening and other 
performance metrics have been collected but do not include 
information on physician follow- up rates, quit rates, or 
the use of pharmacological interventions [10].
Value for money is an important consideration in public 
policy decisions and influences decision- makers in how 
to allocate resources across the health care system. An 
economic evaluation can help inform the costs and effects 
of implementing a smoking cessation initiative within 
Regional Cancer Programs. Much has been published on 
the cost- effectiveness of smoking cessation at the popula-
tion level but there is almost no information related to 
the oncology setting. A recent systematic literature search 
found only one study examining the cost- effectiveness of 
a smoking cessation program implemented at the time 
of surgery for lung cancer [11]. The lack of economic 
evidence to inform decision- makers on the cost- 
effectiveness of smoking cessation programs in persons 
with a new diagnosis of cancer motivated this study.
The objective of this study was to evaluate the potential 
cost- effectiveness of two smoking cessation programs: the 
current basic smoking cessation program and a best prac-
tice smoking cessation program to guide implementation 
of smoking cessation programs across Ontario’s cancer 
system.
Methods
Treatment strategies and target population
We compared two smoking cessation programs: the cur-
rent basic approach to smoking cessation in Regional 
Cancer Programs, which includes only screening, advice 
and referral; and a best practice approach, which includes 
the basic program plus pharmacological therapy (specifi-
cally varenicline), counseling (once a week for 15 min 
with a smoking cessation nurse over 12 weeks), and 
follow- up (Fig. S1) [12]. Our target population was Ontario 
cancer patients aged 65 years. Individuals, 65 years were 
selected as the cohort of interest as that is the average 
age of cancer patients within the Cancer Care Ontario 
smoking cessation program.
Model
A Markov model, with yearly cycle lengths, was developed 
to simulate lifetime health profiles and to compare the 
two cessation programs in a cohort of 65- year- old current 
smokers with cancer (Fig. 1). There were three main states 
in the model: current smokers, former smokers, and death. 
The direction of the arrows indicates possible transitions 
between these three states. Cancer patients who were suc-
cessful with smoking cessation became former smokers 
and from this state, they could either remain a former 
smoker, relapse to become a smoker again, die from 
tobacco- related disease or die from a non- tobacco- related 
cause. Smokers who were unsuccessful in their quit attempt 
remained in the current smoker state. The model assumes 
that current smokers could undertake a self- quit initiative; 
therefore, there was a potential for transition from the 
Figure 1. Decision analytic model.
Former smokersCurrent smokers
Death
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smoker state to the former smoker state in the absence 
of a smoking cessation program. We used data from the 
literature (Table 1) to assign costs, transition probabilities, 
and quality of life utility estimates to each health state 
over a lifetime time horizon. Health benefits were expressed 
as quality- adjusted life- years gained and life- years gained. 
Table 1. Variables used in the model: probabilities, costs, and utilities.
Variable Base case Lower range Upper range Source
12- month abstinence rate in best practice 
program
0.24 0.14 0.36 Ong et al. 2016 [14]
12- month abstinence rate in basic 
program
0.04 0.03 0.05 Fiscella and Franks 
1996 [15], and Orme 
et al. 2001 [16]
Quit due to smoking cessation program 
in year 2
0.02 0.02 0.03 Taylor et al. 2014 and 
Coleman et al. 2010
Self- quit 0.015 0.012 0.018 Stapleton et al. 1999 
[20]
Long- term relapse rates for former smokers
1–2 years 0.24 0.19 0.29 Gilpin, Pierce, and 
Farkas 1997 [32], 
Yudkin et al. 2003 
[33] and Wetter 
et al. 2004 [34]
3–4 years 0.10 0.08 0.12
5–8 years 0.02 0.016 0.024
9–10 years 0.021 0.017 0.025
10+ years 0.005 0.004 0.006
Mortality hazard ratio
Current cancer smokers versus never 1.50 1.07 1.50 Lee et al. 2014 [21]
Former cancer smokers versus never 1.30 0.95 1.81
Background mortality Canadian life tables Statistics Canada
Cancer- related mortality Canadian vital statistics Canadian vital 
statistics death 
database
Smoking cessation nurse fee $105 $95 $116 Average registered 
nurse salary in 
Ontario $35/h 
(15 min × 12 
session) [24]
Best practice program administration cost 
(per patient; one- time cost)
$47 $33 $61 CCO SCP budget 
proposal [10]
Basic program administration cost (per 
patient; one- time cost)
$16 $15 $18 CCO SCP budget 
proposal [10]
Pharmacological therapy (Varenicline) 
(one- time cost)
$150 $105 $195 Ontario drug benefit 
[35]
Annual cancer patient health care cost 
after diagnosis
$25,058 $24,897 $25,219 de Oliveira et al. 2013 
[26]
Smoking- attributable annual cost $403 $262 $486 Norouzi 2012 [25]
Time horizon Lifetime 2 4 Authors’ assumption
Utilities
Former smoker: women
65–74 0.7709 N/a N/a Vogl et al. 2012 [22]
75–100 0.6981
Current smoker: women
65–74 0.7496 N/a N/a Vogl et al. 2012 [22]
75–100 0.6753
Former smoker: men
65–74 0.7802 N/a N/a Vogl et al. 2012 [22]
75–100 0.7358
Current smoker: men
65–74 0.7551 N/a N/a Vogl et al. 2012 [22]
75–100 0.7089
Utility decrement due to cancer 0.12 0.11 0.13 Mittmann et al. 1999 
[23]
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The incremental cost- effectiveness ratio (ICER) was cal-
culated by dividing the difference in expected costs by 
the difference in expected health outcomes between the 
two programs. Both costs and outcomes were discounted 
at 5% per annum [13]. The cost- effectiveness analysis 
was conducted from the perspective of a single healthcare 
payer.
Transition probabilities
The 12- month abstinence rate as a result of the best 
practice smoking cessation program was obtained from 
a study examining the impact of motivational interview-
ing, regular follow- up and pharmacotherapy among 
patients diagnosed with potentially curable cancer [14]. 
After 12 months, patients experienced a lower quit rate. 
The 12- month abstinence rate for the basic smoking ces-
sation program was obtained from three studies which 
consisted of physician advice and pharmacotherapy [15–
17]. After 12 months, we took into a consideration a 
self- quit rate for the basic smoking cessation program. 
The background annual probability to quit and the long- 
term relapse rates were obtained from the clinical literature 
[18–20].
We assumed that all- cause mortality in cancer patients 
included cancer and non- cancer related death. As the 
probability of a cancer death differs between males and 
females, we separated the analysis by sex. As there was 
no direct source of Canadian cause- specific mortality 
stratified by smoking status, we took the following steps 
to calculate the mortality rate by smoking status for cancer 
patients: Step 1, identified the age- specific probability of 
death for male and females in Ontario; Step 2, identified 
the age- specific percentage of cancer and non- cancer deaths 
from all- cause mortality life tables; Step 3, calculated the 
probability of death for cancer and non- cancer status using 
non- cancer death for all- cause mortality; Step 4, identified 
the mortality by age, smoking status, and years of absti-
nence from literature; Step 5, calculated the relative risk 
of mortality by age and smoking status; and Step 6, derived 
the adjusted mortality rates by age, sex, and smoking 
status. Data for the Ontario population were obtained 
from Statistics Canada and the Canadian Vital Statistics 
Death database. We obtained the hazard ratio of mortality 
at 12 months related to tobacco use among patients with 
lung cancer and by smoking status [21].
Utilities
We incorporated health- related quality of life into the 
model using utilities as a measure of the health state 
value for each year by smoking status, age, and sex. Health 
state values were obtained from a study that measured 
the EQ- 5D among smokers, former smokers, and never 
smokers in a general population in the United Kingdom 
(n = 13,241) [22]. We applied a 0.12 utility decrement 
for the cancer patients. This was obtained from a study 
examining the health utilities of 20 chronic conditions in 
the Canadian population (n = 17,626) reported in the 
National Population Health Survey [23].
Costs
We estimated costs from standard costing sources in 
Ontario, Canada, and the published literature. The cost 
of counseling was based on a total of 12 sessions (15 min 
per session over 12 weeks) with a smoking cessation nurse 
[24]. Program administration costs were based on a budget 
proposal developed by Cancer Care Ontario for a smoking 
cessation program in the Regional Cancer Programs [10]. 
The program included the establishment of a Community 
of Practice, provision of evidence- based resources for pro-
gram leads, funding for one full- time tobacco cessation 
counselor to provide onsite coaching, and evaluation of 
the program in each of the 14 regions of the province. 
The program administration cost per cancer patient who 
smoked was calculated by dividing the budgeted annual 
cost by the estimated number of new cancer patients 
smoking in Ontario in 2014. We used a conservative 
approach to determine the cost of cessation medications 
by choosing one of the more expensive pharmacological 
treatments; namely, varenicline (1 mg for 12 weeks), which 
is covered by the Ontario Drug Benefit for individuals 
65 years of age [25]. We assumed that all patients in the 
best practice smoking cessation program took the drug as 
prescribed and attended all follow- up visits. The annual 
cancer patient health care costs after diagnosis were based 
on a population- based descriptive study of the 21 most 
common cancers in Ontario [26]. An estimation of the 
smoking- attributable hospital and physician healthcare 
resource utilization rates were based on a study that obtained 
the health service utilization of smokers from the 2012 
Canadian Community Health Survey. Hospitalization, phy-
sician, and nurse costs were then applied to these health 
care utilization rates. Costs were reported in 2015 Canadian 
dollars. To inflate costs to 2015, the Consumer Price Index 
for health care services in Ontario was used [27].
Sensitivity analysis
We conducted deterministic and probabilistic sensitivity 
analyses to assess the uncertainty of all parameters. We 
conducted a one- way sensitivity analysis on key model 
parameters such as time horizon, abstinence rates, quit rates, 
relapse rates, relative risk of mortality, utility decrement, 
and costs (ranges shown in Table 1). For the probabilistic 
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sensitivity analyses, we used gamma distributions to represent 
uncertainty in the cost parameters because cost data are 
typically skewed and cannot be negative. We used beta 
distributions for the probabilities and utilities because these 
estimates were confined to a 0–1 range. Lognormal distri-
butions were used for the hazard ratio of mortality for 
current and former smokers (Table 1). All parameters were 
randomly sampled from their assigned distributions, and 
10,000 simulations were performed. We estimated the likeli-
hood of each treatment strategy being more favorable across 
a range of Willingness- to- Pay thresholds using cost- 
effectiveness acceptability curves (CEAC). We also summa-
rized the results on a cost- effectiveness plane.
Results
Base case results
In cancer patients, the best practice smoking cessation 
program for smokers was more effective (0.03 QALYs 
gained for males and 0.02 for females) and more costly 
(an additional $101 per patient for males and $41 per 
patient for females) than the basic smoking cessation 
program. For males, the incremental cost- effectiveness 
ratios of the best practice smoking cessation program was 
$3367 per QALY gained and $5050 per LY gained and 
for females, $2050 per QALY gained and $4100 per LY 
gained (Table 2).
Deterministic sensitivity analysis
One- way sensitivity analysis revealed that the results were 
most sensitive to the hazard ratio for mortality for former 
and current smoker cancer patients, the annual health 
care cost of cancer patients after diagnosis, the probability 
of quitting due to the basic smoking cessation program, 
and smoking- attributable cost (Fig. 2). The impact of 
changes in other parameters, such as program administra-
tion cost and the probability of self- quit were less pro-
nounced. When we shortened the time horizon to 2 years, 
the best practice smoking cessation program remained 
more costly and more effective. We also explored a 
Table 2. Incremental cost- effectiveness of smoking cessation in the regional cancer programs of Ontario.
Strategy
Male Female
Cost ($) QALY (discounted) LY (discounted) Cost ($) QALY (discounted) LY (discounted)
Basic smoking cessation 
program
294,859 7.30 11.60 325,638 7.83 12.80
Best practice smoking 
cessation program
294,960 7.33 11.62 325,679 7.85 12.81
Incremental $101 0.03 0.02 $41 0.02 0.01
ICER $3367/QALY $5050/LY $2050/QALY $4100/LY
ICER, Incremental cost- effectiveness ratio; LY, life- year; Program; QALY, quality- adjusted life- year.
Figure 2. One- way sensitivity analysis ICER, Incremental cost-effectiveness ratio.
–300,000 –250,000 –200,000 –150,000 –100,000 –50,000 0 50,000 100,000 150,000
HR of mortality, current smokers
Probability of quing due to program
HR of mortality, former smokers
Cost of smoking
Background mortality
Cost of cancer
Cost of nurse
Probability of self quit
Admin cost for best pracce program
Admin cost for basic program
Incremental cost-effecveness rao values
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scenario that excluded the annual health care costs of 
cancer patients in both arms of the model. In this sce-
nario, the best practice smoking cessation program again 
remained more costly and more effective.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis revealed that the 10,000 
simulated ICERs were located in either the northeast 
quadrant meaning that the intervention was both more 
costly and more effective or the southeast quadrant mean-
ing that the intervention was less costly and more effective 
(Fig. 3). If one QALY gained was valued at Can $50,000, 
then 100% of the simulated ICERs were considered cost- 
effective (Fig. 4).
Discussion
Our results are consistent with previous economic evalu-
ations that used a similar model structure and intervention 
[28, 29]. These models showed that among the range of 
interventions, counseling (with follow- up) plus pharma-
cological therapy was the most cost- effective intervention 
compared to nicotine patch [30, 31]. A smoking cessation 
program implemented at the time of surgery for lung 
cancer has been shown to be a highly cost- effective inter-
vention in a US setting [11].
This study should be interpreted in light of its strengths 
and limitations. First, this study was exploratory in nature 
as data were based on a smoking cessation pilot project 
with limited data on physician follow- up and quit rates. 
We selected the studies that were most applicable to the 
smoking cessation programs offered at the Ontario regional 
cancer center. As such, we relied on clinical evidence 
from broad populations in other countries. We believe 
these studies closely reflect the services offered at the 
cancer centers. This study may not be generalizable to 
other regions that have a different program. Second, we 
used the hazard ratio of current and former smokers’ 
mortality compared to never smokers to show the benefit 
of the smoking cessation program. This parameter was 
quite sensitive and, therefore, splitting the risk of death 
between cancer attributable and non- cancer death could 
Figure 3. Probabilistic sensitivity analysis results on the cost- effectiveness plane. QALYs, Quality-adjusted life years.
Figure 4. Cost- effectiveness acceptability curve. BP-SCP, Best practice-
smoking cessation program; SCP, Basic-smoking cessation program.
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have had a major effect on our results. Third, the model 
did not take into consideration the outcomes and cost 
of other diseases and their comorbidities, such as stroke, 
chronic obstructive pulmonary disease, and cardiovascular 
diseases associated with smoking. If these comorbidities 
were taken into consideration, the best practice smoking 
cessation program could be even more economically attrac-
tive, as smokers are more likely to have other smoking- 
related comorbidities and higher health care costs, which 
we have not included in our model. As well, our model 
considers the cancer patient in “general,” without specify-
ing the particular cancer type or severity. Healthcare 
resource utilization and mortality vary widely depending 
on the type of cancer and severity, which could affect 
the cost- effectiveness of the smoking cessation interven-
tion. Lastly, the model did not take into account any of 
the potential benefits from the reduction in “second- hand 
smoke” exposure to others [28]. Although it is difficult 
to measure the risk from environmental tobacco exposure, 
abstinence from smoking would definitely improve condi-
tions for family members and potentially others.
Further research on smoking- attributable mortality in 
cancer patients is required to improve the validity of the 
parameters used in the model. This is an exploratory 
analysis with many assumptions. It would be important 
to conduct an economic evaluation based on observed 
data from a specific Regional Cancer Program site in 
order to better understand the value for money of a best 
practice smoking cessation intervention.
In conclusion, a best practice smoking cessation program 
for cancer patients has the potential to be an economically 
attractive option when compared to a basic smoking cessa-
tion program over a broad range of assumptions. From this 
analysis, it appears that public funding for a best practice 
smoking cessation program for cancer patients in Ontario 
might be a promising way to reduce economic and healthcare 
burden from smoking in the ambulatory oncology setting.
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